Composite Y Grafts From the Left Internal Mammary Artery: Current Considerations

Left Internal Mammary Artery as an Endocrine Organ: Insights Into Graft Biology and Long-term Impact Following Coronary Artery Bypass Grafting

The left internal mammary artery (LIMA) is considered the criterion standard vessel for use in coronary artery bypass grafting. In recent decades, countless studies have documented its superiority over other arterial and venous coronary artery bypass grafting conduits, although the full mechanisms for this superiority remain unknown. A growing body of literature has unveiled the importance of extracellular vesicles known as exosomes in cardiovascular signaling and various pathologic states. In this review, we briefly compare the clinical longevity of the LIMA relative to other conduits, explore the effects of varying grafting techniques on clinical and angiographic outcomes, and provide physiologic insights into graft function on a cellular and molecular level. Finally, we explore exosome signaling as it pertains to atherosclerosis in support of the LIMA as an "endocrine organ."

Validity of Ipsilateral Internal Mammary Coronary Artery Bypass Graft of Arteriovenous Fistula

BACKGROUND

In coronary artery bypass grafting (CABG) for haemodialysis patients, arteriovenous fistula can reduce blood flow from the internal mammary artery (IMA) graft. The purpose of this study was to delineate the rationale of ipsilateral IMA grafting to the arteriovenous fistula by assessing graft flow and patency.

METHOD

The clinical records of 139 haemodialysis patients who underwent off-pump CABG, including IMA grafting to the left anterior descending artery (LAD) between April 2007 and December 2018, were retrospectively reviewed. Clinical outcomes and transit-time flowmetry results of IMA to LAD bypass grafts during off-pump CABG and postoperative angiography were examined.

RESULTS

An ipsilateral IMA to the arteriovenous fistula (Ipsi-IMA) was used in 89 patients, and a contralateral IMA to the arteriovenous fistula (Contra-IMA) was used in 50 patients and no hospital deaths occurred. The mean graft flow and angiographic patency rate did not differ between the Ipsi-IMA and Contra-IMA groups. In patients with 51 to 90% stenosis of LAD, there was no significant difference in the mean graft flow. In comparison, in the patients with 91 to 100% stenosis of LAD, the mean graft flow in the Ipsi-IMA group was significantly lower than that in the Contra-IMA group (p=0.03). Kaplan-Meier analyses showed a 5-year survival rate of 57.6% for Ipsi-IMA and 64.8% for Contra-IMA (p=0.47).

CONCLUSIONS

In the revascularisation of the LAD, the graft patency rate of the Ipsi-IMA was not inferior to that of the Contra-IMA. However, when the LAD has 91 to 100% stenosis, a Contra-IMA to arteriovenous fistula may be beneficial in terms of sufficient flow capacity.

Radial Artery vs Bilateral Mammary Composite Y Coronary Artery Grafting: 15-Year Outcomes

BACKGROUND

Total arterial coronary revascularization for three coronary territory disease can be achieved with a second arterial conduit joined to the left internal mammary artery as a Y graft, by using either a radial artery (RAY) or a second mammary artery (BIMAY).

METHODS

Patients undergoing total arterial revascularization for three coronary territory disease were identified from two cardiac surgical databases (in Sydney and Melbourne, Australia) using Society of Thoracic Surgeons-based definitions. BIMAY-treated patients underwent surgery between 1994 and 2009, mostly using an age-limited protocol, whereas RAY-treated patients underwent surgery between 1996 and 2003 without age limits. All-cause mortality data were acquired from the national death registry, and survival was estimated by the Kaplan-Meier method. Propensity score matching was performed using 13 variables. Given the age imbalance between the groups, the primary comparison was performed for age 66 years or younger.

RESULTS

Overall, 1896 patients underwent RAY procedures, and 720 patients underwent BIMAY operations. Older age at surgery was the strongest independent predictor of mortality, with a hazard ratio of 2.06, and a 95% confidence interval of 1.93, 2.22 (P < .001). After propensity score matching, we identified 299 pairs of patients 66 years of age or younger with no preoperative or operative differences and similar ages at surgery: RAY 56.4 ± 7.0 years of age vs BIMAY 56.4 ± 6.8 years of age (P = .96). The RAY group had 4.0 ± 0.9 grafts, and the BIMAY group had 3.9 ± 0.9 grafts (P = .814). All-cause mortality was not different, with the proportion surviving at 15 years at 74.9% for the RAY group vs 76.2% for the BIMAY group (P = .211).

CONCLUSIONS

Survival was not different between the RAY and BIMAY groups for total arterial revascularization of three coronary territory bypass grafting.